Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Non-Current Debt (2020 - 2025)

Gain Therapeutics has reported Non-Current Debt over the past 6 years, most recently at $298797.0 for Q3 2025.

  • Quarterly results put Non-Current Debt at $298797.0 for Q3 2025, down 20.56% from a year ago — trailing twelve months through Sep 2025 was $298797.0 (down 20.56% YoY), and the annual figure for FY2024 was $328327.0, down 26.88%.
  • Non-Current Debt for Q3 2025 was $298797.0 at Gain Therapeutics, down from $325359.0 in the prior quarter.
  • Over the last five years, Non-Current Debt for GANX hit a ceiling of $678255.0 in Q1 2021 and a floor of $298797.0 in Q3 2025.
  • Median Non-Current Debt over the past 5 years was $466638.0 (2023), compared with a mean of $466430.8.
  • Biggest five-year swings in Non-Current Debt: dropped 9.33% in 2023 and later dropped 26.88% in 2024.
  • Gain Therapeutics' Non-Current Debt stood at $590468.0 in 2021, then fell by 16.12% to $495258.0 in 2022, then dropped by 9.33% to $449053.0 in 2023, then fell by 26.88% to $328327.0 in 2024, then dropped by 8.99% to $298797.0 in 2025.
  • The last three reported values for Non-Current Debt were $298797.0 (Q3 2025), $325359.0 (Q2 2025), and $314476.0 (Q1 2025) per Business Quant data.